Scientists test new Two-Pronged attack on tough cancers
NCT ID NCT02407509
Summary
This early-stage trial tested a new oral drug, VS-6766, given alone and later combined with another drug called everolimus. The main goal was to find safe and tolerable dosing schedules for patients with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. Researchers also looked for early signs that the treatment could slow cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guy's and St Thomas' Hospital
London, United Kingdom
-
Gynaecological Unit - Royal Marsden NHS Foundation Trust
London, United Kingdom
-
Royal Marsden NHS Foundation Trust
Sutton, Surrey, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.